<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04035837</url>
  </required_header>
  <id_info>
    <org_study_id>ZhuFeng Project</org_study_id>
    <nct_id>NCT04035837</nct_id>
  </id_info>
  <brief_title>The Clinical Cure Project of Chronic Hepatitis B in China</brief_title>
  <official_title>A Study of Peg-interferon Treatment for Nucleos(t)Ide Analogues Suppressed Chronic Hepatitis B Patients With Low Level Hepatitis Surface Antigen</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Third Affiliated Hospital, Sun Yat-Sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Third Affiliated Hospital, Sun Yat-Sen University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Chronic hepatitis B is a global public health problem, with nearly 700,000 deaths each year
      because of hepatitis B-related diseases. Recent studies have found that some patients who
      have used nucleot(s)ide analogues(NAs) for some period can achieve higher hepatitis B surface
      antigen(HBsAg) clearance rate(which is called clinical cure or functional cure) by using
      pegylated interferon. Patients who achieve clinical cure will further reduce liver
      inflammation, fibrosis and risks of liver cirrhosis and cancer in the future. This study was
      initiated in May 2018 and plans to recruit 30,000 eligible patients. The enrollment
      conditions are as follows: 1. according with the diagnosis of chronic hepatitis B in the
      guideline of China in 2015; 2.18-60 years old; 3. more than 1 year history of NAs therapy
      with HBsAg ≤1500 IU/ml, negative hepatitis e antigen and hepatitis B virus DNA＜100 IU/ml; 4.
      no contraindications of interferon. For the above patients, pegylated interferon was used for
      1-2 years(combined with NAs for at least 3 months).The primary goal of this study is to find
      out the optimal treatment for clinical cure.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 16, 2018</start_date>
  <completion_date type="Anticipated">December 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>hepatitis B surface antigen</measure>
    <time_frame>up to 48 weeks</time_frame>
    <description>hepatitis B surface antigen should be tested by the reagents from Roche or Abbott, which is expressed by using IU/ml.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>hepatitis B surface antibody</measure>
    <time_frame>up to 48 weeks</time_frame>
    <description>hepatitis B surface antigen should be tested by the reagents from Roche or Abbott, which is expressed by using IU/ml.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30000</enrollment>
  <condition>Hepatitis B, Chronic</condition>
  <arm_group>
    <arm_group_label>short-course combination group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nucleoside analogue is used during the first 3 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>full-course combination group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nucleoside analogue is used during all the course of study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pegylated interferon-alfa</intervention_name>
    <description>All the patients in this study will receive pegylated interferon for all course.</description>
    <arm_group_label>full-course combination group</arm_group_label>
    <arm_group_label>short-course combination group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  according with the diagnosis of chronic hepatitis B in the guideline of China in 2015

          -  18-60 years old

          -  more than 1 year history of nucleot(s)ide analogues therapy with HBsAg ≤1500 IU/ml,
             negative HBeAg and HBV DNA＜100 IU/ml

          -  no contraindications of interferon

        Exclusion Criteria:

          -  Allergy to interferon

          -  Alanine transaminase &gt;10 times of upper limit of normal(ULN) or total bilirubin &gt;2
             times of ULN

          -  existing or previous decompensated liver cirrhosis

          -  White blood cells or Platelet below the lower limit of normal

          -  existing severe organ injury

          -  combined with autoimmune diseases, psychiatric diseases, diabetes or thyroidism

          -  confirmed or suspected malignant tumors

          -  before or after transplantation

          -  using immunosuppressor

          -  pregnant or having a planned parenthood in 2 years

          -  alcohol or drug addicted

          -  infected by HIV

          -  any conditions that is unsuitable to interferon therapy according to the doctors'
             judgement
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhiliang Gao</last_name>
    <role>Study Chair</role>
    <affiliation>Third Affiliated Hospital, Sun Yat-Sen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zhishuo Mo</last_name>
    <phone>+86 13632434363</phone>
    <email>vbstone@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Infectious Diseases, The Third Affliated Hospital of Sun Yat-sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510630</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhi-Liang Gao, Professor</last_name>
      <phone>86-20-85252373</phone>
      <email>zhilianggao@21cn.com</email>
    </contact>
    <contact_backup>
      <last_name>Xiang Zhu, Doctor</last_name>
      <phone>86-20-85252372</phone>
      <email>0628zhuxiang@163.com</email>
    </contact_backup>
    <investigator>
      <last_name>Zhi-Liang Gao, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Fattovich G, Bortolotti F, Donato F. Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. J Hepatol. 2008 Feb;48(2):335-52. Epub 2007 Dec 4. Review.</citation>
    <PMID>18096267</PMID>
  </reference>
  <reference>
    <citation>Liaw YF, Chu CM. Hepatitis B virus infection. Lancet. 2009 Feb 14;373(9663):582-92. doi: 10.1016/S0140-6736(09)60207-5.</citation>
    <PMID>19217993</PMID>
  </reference>
  <reference>
    <citation>Brunetto MR. A new role for an old marker, HBsAg. J Hepatol. 2010 Apr;52(4):475-7. doi: 10.1016/j.jhep.2009.12.020. Epub 2010 Jan 30.</citation>
    <PMID>20185190</PMID>
  </reference>
  <reference>
    <citation>Liu J, Lee MH, Batrla-Utermann R, Jen CL, Iloeje UH, Lu SN, Wang LY, You SL, Hsiao CK, Yang HI, Chen CJ. A predictive scoring system for the seroclearance of HBsAg in HBeAg-seronegative chronic hepatitis B patients with genotype B or C infection. J Hepatol. 2013 May;58(5):853-60. doi: 10.1016/j.jhep.2012.12.006. Epub 2012 Dec 13.</citation>
    <PMID>23246508</PMID>
  </reference>
  <reference>
    <citation>Tseng TC, Liu CJ, Su TH, Wang CC, Chen CL, Chen PJ, Chen DS, Kao JH. Serum hepatitis B surface antigen levels predict surface antigen loss in hepatitis B e antigen seroconverters. Gastroenterology. 2011 Aug;141(2):517-25, 525.e1-2. doi: 10.1053/j.gastro.2011.04.046. Epub 2011 Apr 28.</citation>
    <PMID>21672542</PMID>
  </reference>
  <reference>
    <citation>Moucari R, Korevaar A, Lada O, Martinot-Peignoux M, Boyer N, Mackiewicz V, Dauvergne A, Cardoso AC, Asselah T, Nicolas-Chanoine MH, Vidaud M, Valla D, Bedossa P, Marcellin P. High rates of HBsAg seroconversion in HBeAg-positive chronic hepatitis B patients responding to interferon: a long-term follow-up study. J Hepatol. 2009 Jun;50(6):1084-92. doi: 10.1016/j.jhep.2009.01.016. Epub 2009 Mar 9.</citation>
    <PMID>19376603</PMID>
  </reference>
  <reference>
    <citation>Dietary effects on diurnal variation in lipogenesis. Nutr Rev. 1987 May;45(5):157-8.</citation>
    <PMID>3601258</PMID>
  </reference>
  <reference>
    <citation>European Association For The Study Of The Liver. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol. 2012 Jul;57(1):167-85. doi: 10.1016/j.jhep.2012.02.010. Epub 2012 Mar 20. Erratum in: J Hepatol. 2013 Jan;58(1):201. Janssen, Harry [corrected to Janssen, Harry L A].</citation>
    <PMID>22436845</PMID>
  </reference>
  <reference>
    <citation>Thompson AJ, Nguyen T, Iser D, Ayres A, Jackson K, Littlejohn M, Slavin J, Bowden S, Gane EJ, Abbott W, Lau GK, Lewin SR, Visvanathan K, Desmond PV, Locarnini SA. Serum hepatitis B surface antigen and hepatitis B e antigen titers: disease phase influences correlation with viral load and intrahepatic hepatitis B virus markers. Hepatology. 2010 Jun;51(6):1933-44. doi: 10.1002/hep.23571.</citation>
    <PMID>20512987</PMID>
  </reference>
  <reference>
    <citation>Ning Q, Han M, Sun Y, Jiang J, Tan D, Hou J, Tang H, Sheng J, Zhao M. Switching from entecavir to PegIFN alfa-2a in patients with HBeAg-positive chronic hepatitis B: a randomised open-label trial (OSST trial). J Hepatol. 2014 Oct;61(4):777-84. doi: 10.1016/j.jhep.2014.05.044. Epub 2014 Jun 7.</citation>
    <PMID>24915612</PMID>
  </reference>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>July 13, 2019</study_first_submitted>
  <study_first_submitted_qc>July 24, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 29, 2019</study_first_posted>
  <last_update_submitted>July 24, 2019</last_update_submitted>
  <last_update_submitted_qc>July 24, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 29, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Third Affiliated Hospital, Sun Yat-Sen University</investigator_affiliation>
    <investigator_full_name>Zhiliang Gao</investigator_full_name>
    <investigator_title>The director of the infectious diseases department</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Study protocol would be shared with other researchers.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

